Меню
Идёт набор NCT07554820

Major Adverse Cardiovascular Events (MACE) in Rheumatoid Arthritis Patient With Moderate to Severe Disease Activity Treated With Tofacitinib and Statins vs TNF Inhibitors: TOFSTAT CLINICAL TRIAL

Фаза IV С лечением Rheumatoid Arthritis Major Adverse Cardiac Events

Ориентир для пациента и семьи

Простыми словами

Автоматическая сводка по структурированным данным реестра. Она помогает сориентироваться, но не заменяет официальный протокол или оценку врача.

Что изучают
В протоколе указаны: Tofacitinib 5 MG.
Кому может быть актуально
Состояния в реестре: Rheumatoid Arthritis, Major Adverse Cardiac Events. Базовые параметры: 50 лет — 85 лет · Все.
Что важно проверить
Возраст, диагноз и пол — только базовые ориентиры. Предыдущее лечение, анализы и другие обязательные условия указаны ниже в критериях участия.
Где проводится
Пакистан
Следующий шаг
Сохраните исследование, покажите его лечащему врачу и уточните актуальный статус у исследовательского центра. Расходы, документы и поездка →

Не всё понятно в терминах? Прочитайте наш гид для пациентов →

Обзор

The rationale of our study is to observe the incidence of MACE in RA patients treated with tofacitinib along with statins with one or more cardiovascular disease risks. PRIMARY OBJECTIVE * To determine the incidence of MACE in Rheumatoid Arthritis patients with moderate to high disease activity and with one or more cardiovascular disease risks, which are non-responsive to standard conventional DMARDs (cDMARDs) treatment and are prescribed Tofacitinib 5 mg twice daily along with statin 20 mg daily versus TNF Inhibitors. * The study aim to compare MACE in RA patients treated with tofacitinib and statin versus TNF inhibitors.

Подробное описание

This study is a prospective non randomized Clinical Trial Phase-4 aimed at observing the incidence of MACE in RA patients who have moderate to severe disease activity (as determined by the DAS-28 score) and one or more cardiovascular disease (CVD) risks. The patients included in the study will have non-responsiveness to standard cDMARDs treatment and will be prescribed tofacitinib 5 mg twice daily along with statins 20 mg daily as risk modification versus TNF Inhibitor as standard treatment will be the control group.

METHODOLOGY

* Initial Assessment:

* Baseline evaluation including DAS-28 score, lipid profile, and assessment of CVD risk factors (hypertension, diabetes, smoking, cholesterol levels, etc.). * Recruitment of patients based on inclusion and exclusion criteria. * Intervention:

* In one group tofacitinib (5 mg twice daily) and statins (atorvastatin 20 mg daily) will be added to the treatment regimen of the patients. * In control group TNF inhibitor will be added to the treatment regimen of the patients as part of standard treatment. * Patients will be followed up monthly for a period of 6 months. * Monthly assessments during follow up: Lipid profile Total cholesterol, LDL, HDL, triglycerides, DAS-28 score, Recording of any CVD events (MACE), Monitoring of any other related complications. * Tofacitinib Discontinuation:

o If a patient experiences a CVD event, tofacitinib will be stopped and documented. * Follow up:

* Monthly visits for a 6 month, during which patient progress and any adverse events will be recorded. * If a MACE occurs, treatment with tofacitinib will be discontinued, and the event will be thoroughly documented.

Вмешательства

  • Препарат Tofacitinib 5 MG
    * In one group tofacitinib (5 mg twice daily) and statins (atorvastatin 20 mg daily) will be added to the treatment regimen of the patients. * In control group TNF inhibitor will be added to the treatment regimen of the patients as part of standard treatment. * Patients will be followed up monthly for a period of 6 months. * Monthly assessments during follow up will include Lipid profile Total cholesterol, LDL, HDL, triglycerides. DAS-28 score. Recording of any CVD events (MACE). Monitoring of a

Первичные конечные точки

  • Major Adverse Cardiovascular Event [Срок оценки: 6 months]
  • Compare Incidence of MACE in two group [Срок оценки: 6 months]
Вторичные конечные точки (2)
  • effectiveness of tofacitinib in controlling disease activity [Срок оценки: 6 months]
  • lipid profile [Срок оценки: 6 months]

Критерии участия

Критерии включения

  • • RA diagnosis with moderate to severe disease activity, based on DAS-28 despite on > 2 conventional DMARDs.
  • One or more CVD risk factors, such as hypertension, diabetes, smoking, high cholesterol, etc.
  • Age 50 or older.

Критерии исключения

  • Known contraindications to statins.
  • History of major adverse CV events (e.g., recent myocardial infarction or stroke).
  • Pregnancy or breastfeeding.

Критерии приведены из реестра в оригинале (на английском). Окончательную оценку соответствия проводит исследовательский центр.

Здоровые добровольцы: Нет

Дизайн исследования

Распределение
Нерандомизированное
Модель
Параллельные группы
Маскирование
Открытое
Основная цель
Лечение

Центры проведения

Пакистан · 1 центр
  • Shaikh Zayed Hospital, Lahore — Lahore

Идентификаторы

NCT: NCT07554820 · 01-TERC/NHRC-SZH/FB/939

Первоисточники (государственные реестры)

Открыть это исследование на ClinicalTrials.gov ↗